SPOTLIGHT: DeCode launches genetic trial

Iceland's DeCode Genetics has launched a closely watched Phase III trial of DG031 to prevent heart attacks. The company will track the results of 3,400 African-American subjects who have a genetic variant linked to heart attacks. Report

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.